The goal of this clinical trial is to learn whether teduglutide, a medicine that helps the intestine heal, can improve environmental enteric dysfunction in undernourished women aged 18 to 35 years living in urban slums of Dhaka.
Environmental enteric dysfunction is a long-lasting condition of the small intestine. It causes inflammation and poor absorption of nutrients. Many people with this condition do not have clear symptoms, but it can make undernutrition worse. At present, there is no proven treatment for this condition.
The main questions this study aims to answer are:
* Does taking teduglutide for 30 days improve damage to the small intestine, as seen on intestinal biopsy?
* Does teduglutide improve blood and stool markers related to gut inflammation and nutrient absorption?
Participants will:
* Receive nutritional support at the start of the study
* Undergo an upper gastrointestinal endoscopy to confirm environmental enteric dysfunction
* Receive a daily injection of teduglutide under the skin for 30 days
* Undergo repeat endoscopy and laboratory tests after treatment to assess changes in gut health The results of this study will help researchers understand whether teduglutide may be a useful treatment for environmental enteric dysfunction in undernourished adult women and will guide future, larger studies.

开始日期2026-07-01

申办/合作机构

International Centre for Diarrhoeal Disease Research, Bangladesh

NCT06973304

/ Recruiting临床3期

An Open-label, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of 0.05 mg/kg/Day Subcutaneous Teduglutide Following Treatment of Short Bowel Syndrome for 24 Weeks in Chinese Adults Who Are Dependent on Parenteral Support

The main aim of the study is to assess how well teduglutide works over 24 weeks in Chinese adult participants with short bowel syndrome (SBS) who need parenteral support and to see how much it can reduce the amount of parenteral support and understand how the body absorbs, processes, and gets rid of teduglutide.
Participants will receive a daily injection of teduglutide under the skin for 24 weeks. Safety of teduglutide will be checked for 24 weeks after treatment.
Participants will be in the study for about 65 weeks.

开始日期2025-06-26

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

ChiCTR2500095623

/ Not yet recruiting临床4期IIT

Efficacy of Teduglutide in the treatment of acute myocardial infarction: a prospective single-center randomized controlled study

开始日期2025-01-01

申办/合作机构

安徽医科大学第一附属医院

100 项与替度格鲁肽相关的临床结果

登录后查看更多信息

100 项与替度格鲁肽相关的转化医学

登录后查看更多信息

100 项与替度格鲁肽相关的专利（医药）

登录后查看更多信息

265

项与替度格鲁肽相关的文献（医药）

2026-05-01·CURRENT OPINION IN GASTROENTEROLOGY

Glucagon-like peptide agonists and use in short bowel syndrome – what about the side effects?

Review

作者: Boucher, Megan ; Rutter, Charlotte ; Gorard, Lucy

Purpose of review:

This review summarizes recent evidence on the use of glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) agonists in the management of short bowel syndrome (SBS), with a focus on emerging therapies and real-world experience. It evaluates their impact on intestinal adaptation, safety, and future clinical potential.

Recent findings:

GLP-2 agonists such as teduglutide continue to demonstrate improvements in intestinal absorption resulting in reductions in parenteral support (PS) requirements and improved quality of life. Clinical trials report that newer long-acting agents, such as apraglutide and glepaglutide, allow less frequent dosing with a reduction in PS and structural intestinal changes on imaging. Safety profiles remain favourable, with gastrointestinal symptoms, fluid balance issues, gallbladder events and injection-site reactions reported most frequently. GLP-1 agonists show promise in slowing transit time and offer an area for further research.

Summary::

While GLP-2 agonists shape the current landscape of SBS management, GLP-1 based therapies may complement future treatment strategies offering the potential to reduce or even eliminate dependence on PS. Continued long-term studies and registry data are essential to optimize patient selection, safety monitoring, and personalized use of GLP agonists.

2026-04-01·CLINICAL PHARMACOKINETICS

Systemic Pharmacokinetic Principles of Therapeutic Peptides

Article

作者: Gennemark, Peter ; Nordell, Pär ; Jansson-Löfmark, Rasmus

INTRODUCTION:

Peptide-based therapeutics represent a rapidly expanding class of drugs. Endogenous peptides typically exhibit short elimination half-lives due to proteolytic cleavage and renal filtration. However, modifications such as amino acid substitutions and fatty-acid conjugation can significantly prolong their half-lives, enabling, for example, once weekly dosing. This study revisits the systemic pharmacokinetics of peptide drugs using classical pharmacokinetic principles and elucidates the scaling of peptide pharmacokinetics across species.

METHODS:

Preclinical and clinical pharmacokinetic data were collected from published literature and AstraZeneca internal sources, covering four unconjugated peptides (teduglutide, apraglutide, pramlintide, and exenatide) and five fatty-acid conjugated peptides (tirzepatide, cotadutide, liraglutide, semaglutide and pemvidutide). Algebraic equations for clearance, volume of distribution, and plasma half-life were derived.

RESULTS:

Theoretical predictions from these models were broadly consistent with collected data; however, there was a tendency to overpredict the volume of distribution. Furthermore, for each peptide drug, these pharmacokinetic parameters were well described by inter-species allometric relationships. The allometric exponents for apparent clearance ranged from 0.58 to 0.88 (geometric mean: 0.72; n = 9; R² ≥ 0.93), while those for apparent volume of distribution ranged from 0.89 to 1.1 (geometric mean: 0.98; n = 8; R² ≥ 0.88). Notably, there were no differences in scaling exponents between unconjugated and fatty-acid conjugated peptides.

CONCLUSION:

In summary, our results underscore that the systemic pharmacokinetics of peptide drugs generally follow size-related physiological scaling patterns and provide quantitative tools to facilitate translational assessments in the drug discovery process.

2026-04-01·Intestinal Failure (New York, N.Y.)

Teduglutide use in haemodialysis-dependent renal failure from secondary hyperoxaluria in short bowel syndrome and type 3 intestinal failure – A case report

Article

作者: Low, Elizabeth Sl ; Wong, Darren ; Chapman, Brooke

Background:

Renal impairment is common in patients receiving long-term home parenteral nutrition (HPN) for short bowel syndrome-associated intestinal failure (SBS-IF). While glucagon-like peptide-2 (GLP-2) analogues like teduglutide are effective in reducing parenteral support (PS) requirements, data on their use in advanced stage chronic kidney disease (CKD) or haemodialysis are scarce.

Case report:

We describe a 66-year-old female with SBS-IF on HPN, complicated by hyperoxaluria and nephrocalcinosis contributing to stage 4 CKD. Initial renally-adjusted teduglutide dosing (0.025 mg/kg/day) enabled enteral autonomy, but was interrupted by intercurrent illness. As a result of progressive renal dysfunction, the patient was commenced on haemodialysis. Teduglutide was introduced post-dialysis at full dose (0.05 mg/kg), resulting in a sustained 36 % reduction in weekly PS requirements without adverse effects, despite recurrent sepsis.

Conclusion:

This case demonstrates a clinically significant teduglutide response in a haemodialysis-dependent SBS-IF patient, supporting post-dialysis dosing as a feasible strategy in this HPN cohort.

151

项与替度格鲁肽相关的新闻（医药）

2026-05-05

·BioSpace

British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome

TORONTO , May 5, 2026 /CNW/ - Takeda Canada Inc. ("Takeda") announced that REVESTIVE ® (teduglutide for injection) will now be reimbursed by BC PharmaCare for eligible pediatric and adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support. 1 Coverage is subject to specific criteria. 2 For people living with SBS, reimbursed access can help reduce reliance on parenteral support, which includes intravenous administration of nutrition, fluids, and electrolytes. "We welcome the Government of B.C.'s decision to reimburse REVESTIVE for people living with Short Bowel Syndrome. This decision is an important step toward improving equitable access to care and supporting better health outcomes," said Gail Attara, CEO and Co-founder of the Gastrointestinal Society and President of the Canadian Society of Intestinal Research. "Patient organizations have long engaged with provincial governments on the need for timely access to therapies for rare digestive disorders. We look forward to continuing to work collaboratively with policymakers and partners to strengthen access to appropriate treatments for Canadians living with complex GI conditions." SBS occurs when the small intestine is unable to absorb enough nutrients and fluids – often due to surgical removal, damage, or disease. 3 People living with SBS may experience dehydration, malnutrition, fatigue, and weight loss, among other serious health impacts. 3 Management can include medications, surgery, and significant dietary changes. 4 SBS affects approximately 800 Canadians and has an estimated mortality rate of almost 40 per cent. 5 "Many people living with SBS rely on parenteral support delivered intravenously (IV). While lifesaving, IV support can be associated with serious complications and can significantly affect quality of life for patients and caregivers," said Dr. Andrea Martinez, Medical Director, Complex Feeding and Nutrition Service, BC Children's Hospital. "REVESTIVE has been shown to help some patients reduce their need for parenteral support, which can translate into meaningful improvements not only in day-to-day life but also in long-term outcomes." Health Canada issued a Notice of Compliance for REVESTIVE in 2015 for the treatment of adult patients with SBS who are dependent on parenteral support. It was approved in Canada for pediatric patients one year of age and above for the same indication in 2019. "This reimbursement is another step forward for people in B.C. living with Short Bowel Syndrome, improving access to a therapy that can help eligible patients reduce reliance on parenteral support," said Thiago Magalhães, Business Unit Head, GI² and Mature Brands. "REVESTIVE reflects Canadian innovation, rooted in the discovery of Glucagon-like peptide-2 (GLP-2) at the University of Toronto and advanced through Canadian research, development, and clinical participation." About REVESTIVE ® REVESTIVE ® (teduglutide for injection) is currently indicated in Canada for the treatment of adults and pediatric patients one year of age and above with Short Bowel Syndrome who are dependent on parenteral support. 1 About Short Bowel Syndrome with Intestinal Failure Short bowel syndrome–associated intestinal failure (SBS-IF) is characterized by reduced gut absorptive function below the minimum necessary for absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation (parenteral nutrition and/or IV fluids/electrolytes) is required to maintain health. When intestinal adaptation is inadequate following extensive intestinal resection or injury, patients may require chronic parenteral support to maintain hydration and nutrient balance. 6 , 7 , 8 About Takeda Canada Inc. Takeda Canada Inc. is the Canadian organization of Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) , a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit: . _______________________________________ 1 REVESTIVE (Teduglutide for injection), Submission Control 296120, Product Monograph, Takeda Canada Inc. (SEP 19, 2025). Available at: . 2 Drug Coverage Decision for BC PharmaCare. Available at: (accessed April 2026). 3 GI Society, Canadian Society of Intestinal Research. Short Bowel Syndrome. Available at: Short Bowel Syndrome | Gastrointestinal Society . 4 O'Keefe SJD, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. (2006). Short bowel syndrome and intestinal failure: Consensus definitions and overview. Clin Gastroenterol Hepatol; 4:6-10. 5 Amin S, Pappas C, Lyengar H, Maheshwari A. Short Bowel Syndrome in the Nicu. Clin Perinatol. 2013 Jan 17;40(1):10.1016/j.clp.2012.12.003. doi: 10.1016/j.clp.2012.12.003. PMID: 23415263; PMCID: PMC3886240. Available at: Short Bowel Syndrome in the Nicu - PMC . 6 Pironi L, et al. ESPEN guideline on chronic intestinal failure in adults – Update 2023. Clinical Nutrition. 2023 Oct;42(10):1940–2021. doi:10.1016/j.clnu.2023.07.019. PMID: 37639741. (guidelinecentral.com). 7 Wauters L, Joly F. Treatment of short bowel syndrome: Breaking the therapeutic ceiling? Nutr Clin Pract. 2023 May;38(Suppl 1):S76–S87. doi:10.1002/ncp.10974. PMID: 37115030. (pubmed.ncbi.nlm.nih.gov). 8 Bering J, DiBaise JK. Short Bowel Syndrome in Adults. Am J Gastroenterol. 2022 Jun 1;117(6):876–883. doi:10.14309/ajg.0000000000001763. PMID: 35383576. (pubmed.ncbi.nlm.nih.gov). SOURCE Takeda Canada Inc.

2026-04-17

·交叉坐标实验室

文章分享 | 多肽类药物研发现状

文章来源：Pharmacy Information, 2025, 15: 1. 作者：薛周元，邱郑（中国药科大学生命科学与技术学院） DOI：10.12677/pi.2026.151001 发布日期：2026年1月近年来，多肽药物研究取得了显著进展，越来越多的多肽药物被开发并应用于临床。多肽药物在肿瘤、抗菌、心血管疾病、糖尿病等领域的预防、诊断和治疗中得到了广泛应用，并展现出广阔的发展前景。本文旨在系统综述多肽药物的来源、特点、先导多肽发现策略，以及在不同疾病治疗领域的国内外研发概况。1. 多肽药物概述1.1 基本概念多肽是由少于100个氨基酸残基通过肽键连接而成的化合物，相对分子质量通常低于10000 Da，一般在500-5000 Da之间。自1921年第一个多肽类激素胰岛素被发现至今，多肽药物的研究已取得令人瞩目的进展。市场规模：全球多肽市场2023年规模为414.4亿美元预计2024年增至456.6亿美元，年复合增长率达10.2% 预计2028年攀升至688.3亿美元，年复合增长率提升至10.8% 研发管线：全球已获批上市的多肽药物超过80种超过200种处于临床开发阶段超过600种正在进行临床前研究1.2 作用靶点已上市的多肽药物主要针对G蛋白偶联受体类蛋白质，临床研发中的肽类药物有90%以上作用于细胞外靶点，如： GLP-1受体 GnRH受体生长激素受体生长抑素受体1.3 优缺点优势：高度选择性和特异性结合亲和力较低的全身毒性和脱靶效应免疫原性较低，生产成本较小不易在体内蓄积，药物相互作用少挑战：细胞膜不渗透性：无法有效穿透细胞膜作用于细胞内靶点体内稳定性差：易被酶水解，半衰期短，体内消除快2. 多肽药物的发现多肽药物的发现主要有三种途径：2.1 基于内源性配体从自然界存在的生命体中提取分离多肽分子，再通过活性测定筛选具有开发价值的活性多肽。典型案例： GLP-1衍生肽：度拉糖肽、利拉鲁肽、司美格鲁肽，用于2型糖尿病治疗 GnRH衍生肽：亮丙瑞林、地加瑞克，用于前列腺癌等治疗培莫沙肽（2023年我国自主研发）：长效EPO模拟肽，用于肾性贫血2.2 基于天然产物源于细菌、真菌、植物及动物的天然生物活性肽。典型案例：蛇毒肽：作为VEGF类似物，作用于离子通道 Tyroserleutide (YSL)：三肽化合物，对原发性肝细胞癌表现出治疗活性，已推进至III期临床试验非核糖体肽：包括万古霉素、环孢素，对水解酶抗性更强3. 多肽药物在各疾病领域的应用3.1 糖尿病治疗 GLP-1类似物（GLP-1受体激动剂）是研究最广泛的多肽药物。核心机制：刺激胰岛β细胞释放胰岛素抑制胰高血糖素分泌减慢胃排空速率，减少能量消耗代表性药物：利拉鲁肽：通过脂肪酸修饰与白蛋白结合，延长半衰期司美格鲁肽：可每周一次皮下注射或每日一次口服洛塞那肽：国内首款上市长效GLP-1RA，豪森药业自主研发诺利糖肽：国内研发，正处于临床II期3.2 抗癌肽多肽在肿瘤治疗领域涵盖四大策略：肿瘤诊断成像、药物偶联递送、多肽疫苗、直接治疗。代表性药物：卡非佐米：第二代蛋白酶体抑制剂，用于复发性和难治性多发性骨髓瘤阿普立定：靶向eEF1A2，2019年在澳大利亚获批用于多发性骨髓瘤西仑吉肽：首个肽类整合素拮抗剂，靶向αvβ3和αvβ5整合素 NP-12：与PD-L1竞争性结合，在黑色素瘤、结肠癌模型中表现优异 Lutetium 177-Dotatate：放射性标记生长抑素类似物，用于胃肠神经内分泌肿瘤成像探针： Octreoscan：生长抑素受体闪烁扫描，已获FDA批准 GEBP11：九肽，特异性结合肿瘤相关血管3.3 抗菌肽抗菌肽通过作用于细菌细胞膜，促使膜渗透性增加，诱导生物膜溶解导致细菌死亡。代表性药物：奥利万星：万古霉素半合成变体，用于革兰氏阳性菌感染 Nisin：最早发现的羊毛硫细菌素 OMN6：基于天蚕素的40个氨基酸抗菌环肽，针对多重耐药革兰氏阴性菌，处于临床I期 Pexiganan：源自非洲爪蟾皮肤的蛙皮素类似物，用于糖尿病足溃疡，处于III期临床3.4 抗病毒多肽代表性药物：恩福韦肽：首个获批的抗病毒肽，用于HIV联合治疗波西普韦/特拉匹韦：用于丙型肝炎，靶向NS3/4丝氨酸蛋白酶阿肤地尔：28个氨基酸VIP类似物，2021年获批用于COVID-19治疗3.5 其他疾病领域 BBT-401：Pellino-1抑制剂，用于溃疡性结肠炎 Forigerimod：21个氨基酸线性肽，用于系统性红斑狼疮 Teduglutide：GLP-2类似物，用于短肠综合征 Zilucoplan：补体C5抑制剂，2023年获批用于全身性重症肌无力4. 多肽药物未来发展4.1 多功能肽研发焦点集中在GLP-1激动剂的创新，未来将发展同时激活两个或三个不同受体的双/三激动剂。代表性管线：替尔泊肽：GLP-1/GIP双受体激动剂，每周一次皮下注射 Cotadutide：GLP-1R/GCGR双激动剂，处于临床II期 LY3437943：GLP-1/GCGR/GIPR三重激动剂（礼来公司）4.2 多肽药物缀合物多肽与小分子药物、寡核苷酸乃至抗体的缀合，尤其在肿瘤治疗领域最为火热，已有超过20种缀合物进入临床试验阶段。4.3 多肽疫苗多肽疫苗展现出成本更低、安全性更高及特异性更强的特点。研究进展： NeoVax：治疗黑色素瘤的肽疫苗，I期临床试验显示可诱导长期持续性T细胞免疫反应 AtheroVaxTM：靶向sTNFR2的肽疫苗，在小鼠模型中显著抑制动脉粥样硬化进展目前尚无基于肽的疫苗上市，多数在临床试验中未能充分展示预期成效。5. 结语与展望当前，化学合成与生物重组技术的单独或联合应用，确保了大规模肽合成的高效性。多肽药物面临的主要挑战仍是膜透过性不佳和体内稳定性不足。未来发展方向：结构改造策略：多肽与大分子偶联、前药设计、肽环化、末端修饰、氨基酸替换多样化剂型探索：提高患者依从性人工智能辅助研发：通过构建机器学习或深度学习模型，高效筛选大量潜在治疗性肽序列 AI+研发模式预计将加速肽类药物的创新进程，为疾病治疗带来新的动力。总结多肽药物在糖尿病、肿瘤、抗感染、自身免疫疾病等领域展现出巨大潜力。从传统激素模拟到多功能肽、药物缀合物、多肽疫苗，创新技术不断推动该领域繁荣发展。随着结构改造策略的完善和人工智能技术的赋能，多肽药物有望在未来攻克口服递送等关键瓶颈，成为创新药物研发的重要支柱。

2026-04-06

·全科医学教育

文献｜嗜酸性胃肠病与吸收不良综合征：诊断标准、临床表型及治疗新进展

公众号AI功能可回答部分医学问题，关注后使用👆🏻👆🏻👆🏻 每日7：47定时更新每周7篇简短综述声明:仅供医学专业人士参考，注意鉴别。阅读改变自己，分享改变世界嗜酸性胃肠病与吸收不良综合征：诊断标准、临床表型及治疗新进展内容AI生成，仅供参考，务必阅读原文🎯 综述摘要这组文献聚焦于胃肠道复杂疾病的诊疗现状与前沿进展，涵盖了吸收不良、嗜酸粒细胞性胃肠病（EGID）及自身免疫性胃炎（AIG）三大领域。文献不仅系统阐述了吸收不良的定义、诊断路径及营养支持策略（如替度鲁肽在短肠综合征中的应用），还深入探讨了EGIDs的流行病学演变、自然史（包括从炎症向纤维化的进展）及治疗新靶点（如生物制剂）。同时，针对自身免疫性胃炎的隐匿性、与肿瘤风险的关系以及非EoE EGID的异质性诊断难题进行了综述。整体旨在为临床医生提供从基础机制到临床管理的全面视角，并指出当前在标准化诊断和治疗指南方面的挑战与未来方向。💡 临床实践启示警惕隐匿性病因与多学科协作：在诊断吸收不良或不明原因的胃肠道症状时，应始终将乳糜泻（CD）作为排查对象，并提高对自身免疫性胃炎（AIG）的警惕，尤其是在幽门螺杆菌感染率下降的背景下，关注其与胃癌及神经内分泌肿瘤的风险关联 Lenti et al. (2025) Ahn et al. (2025) 。全科医生应发挥核心作用，参与多学科团队（MDT）以提高早期发现率 Lenti et al. (2025) 。关注嗜酸粒细胞性胃肠病（EGID）的谱系差异：除嗜酸性食管炎（EoE）外，需重视非EoE EGIDs（如胃炎、肠炎）的异质性诊断，注意病变可累及黏膜层、肌层乃至浆膜，且病程呈持续性或进行性，避免漏诊 Visaggi et al. (2026) Lam et al. (2025) 。在治疗EoE时，应关注从炎症向纤维化重塑的进展过程 Visaggi et al. (2026) 。灵活应用新型治疗手段：对于短肠综合征患者，可考虑使用替度鲁肽减少对肠外营养的需求；在EGID治疗中，应依据最新指南灵活应用生物制剂（如度普利尤单抗）及饮食排除疗法，以改善患者生活质量 Lenti et al. (2025) Visaggi et al. (2026) Wright et al. (2024) 。🔭 科研选题建议选题1：自身免疫性胃炎（AIG）的早期诊断标志物与胃癌风险分层研究选题依据：AIG诊断往往被延误，缺乏标准化的血清学或活检指南，且与胃癌风险关系复杂。随着幽门螺杆菌感染率下降，研究旨在探索新的生物标志物，明确AIG的流行病学变化及其癌前病变机制 **Ahn et al. (2025)**。选题2：非EoE嗜酸粒细胞性胃肠疾病（Non-EoE EGID）的组织学诊断标准与分层治疗策略选题依据：非EoE EGIDs具有高度异质性和诊断挑战性，针对肌层和浆膜受累的评估手段尚不统一。研究可致力于制定基于共识命名法的组织学评估指南，并探索针对不同分层病变的靶向治疗（如生物制剂）疗效 **Lam et al. (2025)**。选题3：度普利尤单抗在非EoE EGIDs及短肠综合征中的临床应用与机制研究选题依据：虽然EoE治疗已成熟，但非EoE EGIDs和短肠综合征的管理仍需突破。利用2024年最新研讨会数据，探讨生物制剂在非EoE EGIDs中的疗效及替度鲁肽改善生活质量的具体机制 **Visaggi et al. (2026) Wright et al. (2024)**。✍️ 论文写作与设计借鉴亮点：结构严谨与全面性。如论文 Lenti et al. (2025) 采用“定义-诊断-管理-全科医生视角”的模块化结构，涵盖从病理生理到基层医疗的全链条；论文 Visaggi et al. (2026) 清晰区分EoE与非EoE，并深入探讨了自然史（如纤维化重塑），体现了从“现象”到“机制”的深度 Lenti et al. (2025) Visaggi et al. (2026) 。不足：证据等级参差与指南空白。部分综述（如论文 Ahn et al. (2025) ）主要基于现有文献回顾，缺乏前瞻性临床数据支持；论文 Lam et al. (2025) 指出非EoE EGIDs的诊断标准尚在制定中，提示当前证据基础相对薄弱，存在较大的研究空白 Ahn et al. (2025) Lam et al. (2025) 。📝 原文摘要与核心数据论文 Lenti et al. (2025) ：European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN. Part 1: Definitions, Clinical Phenotypes, and Diagnostic Testing for Malabsorption. 原文题目：欧洲关于吸收不良的共识——UEG & SIGE、LGA、SPG、SRGH、CGS、ESPCG、EAGEN、ESPEN 和 ESPGHAN。第一部分：吸收不良的定义、临床表型及诊断测试研究目的：本文旨在通过欧洲多学会专家共识，剖析吸收不良相关的定义、临床表型及诊断测试等问题。原文摘要：吸收不良是一种复杂且多面的状况，其特征是营养物质进入血液和淋巴流的通道受损。多种先天性或后天性疾病可能导致儿童和成人出现选择性或全身性吸收不良，例如囊性纤维化、外分泌胰腺功能不全（EPI）、乳糜泻（CD）及其他肠病、乳糖酶缺乏、小肠细菌过度生长（SIBO）、自身免疫性萎缩性胃炎、克罗恩病以及胃或小肠切除术。早期识别吸收不良对于制定适当的诊断方案以确定其病因至关重要。患者的病史和用药史对于识别风险因素至关重要。诸如小肠镜活检、无创功能检查和影像学检查等几种检查手段在诊断吸收不良时很有帮助。由于乳糜泻（CD）的高患病率，在原因不明的吸收不良病例和高危个体中，应始终将其作为排查对象。营养支持是管理吸收不良患者的关键；不同的方案可供选择，包括口服补充剂、肠内或肠外营养。对于短肠综合征患者，替度鲁肽被证明能有效减少对肠外营养的需求，从而改善患者的生活质量。全科医生在早期发现吸收不良方面发挥着核心作用，应参与多学科团队以提高对这些患者的整体管理水平。在这项涉及十个科学学会和多位专家的欧洲共识中，我们剖析了围绕吸收不良的所有问题，包括定义和诊断测试（第一部分）、高危类别和特殊人群、营养评估和管理以及全科医生视角（第二部分）。论文 Lenti et al. (2025) ：Epidemiology, Natural History, and Treatment of Eosinophilic Gastrointestinal Diseases. 原文题目：嗜酸性胃肠病的流行病学、自然史和治疗研究目的：本文综述了嗜酸性胃肠病（EGIDs）的流行病学、自然史、风险因素及治疗策略的最新进展，涵盖嗜酸性食管炎（EoE）和非EoE EGIDs。原文摘要：嗜酸性胃肠病（EGIDs）是一种由胃肠道内嗜酸性粒细胞为主的病理性浸润驱动的慢性炎症性疾病。根据炎症是否仅局限于食管或其他胃肠道节段，命名系统将EGIDs分为嗜酸性食管炎（EoE）和非EoE EGIDs。由于过去30年来发病率持续上升且目前未观察到平台期（尤其是EoE），EGIDs正迅速成为胃肠病学领域的关注焦点。EGIDs不断变化的流行病学特征与多种早期生活及环境风险因素相关。近年来，人们对EGIDs自然史的认识也已成熟：在EoE中，已识别出从炎症向纤维化重塑进展的过程；在非EoE EGIDs中，已认识到存在累及黏膜层、肌层和浆膜的病变，且病程呈持续性、进行性或复发缓解交替模式。EGIDs的药物治疗领域也得到了显著扩展。目前，质子泵抑制剂、口服局部糖皮质激素、饮食排除疗法和度普利尤单抗被推荐用于EoE治疗。系统性或局部糖皮质激素、饮食排除疗法、质子泵抑制剂以及部分生物制剂在非EoE EGIDs中显示出疗效（主要基于观察性研究），针对EGIDs设计的新型药物也正在研究中。本综述讨论了EoE和非EoE EGIDs在流行病学、自然史和风险因素方面的最新进展，并根据最新的临床指南更新了治疗策略，概述了知识空白以指导未来的研究方向。论文 Ahn et al. (2025) ：Autoimmune Gastritis: Unveiling the Mystery. 原文题目：自身免疫性胃炎：揭示神秘面纱研究目的：旨在概述自身免疫性胃炎的当前发现，探讨未解问题，以阐明其复杂的发病机制、临床意义及潜在管理策略。原文摘要：萎缩性胃炎主要由幽门螺杆菌感染和自身免疫机制引起。在幽门螺杆菌感染率仍然很高的韩国，尚未制定用于诊断自身免疫性胃炎（AIG）的血清学检测或活检的标准化指南。最近，随着幽门螺杆菌感染率的下降，与胃癌和胃神经内分泌肿瘤（gNENs）相关的趋势发生了转变，对AIG的兴趣日益增加，尤其是在亚洲。然而，由于缺乏警惕，AIG的诊断往往被延误；即使考虑到了AIG，对疾病的有限理解也阻碍了其准确诊断。此外，缺乏既定的治疗方案和标准化的随访协议给患者管理带来了重大挑战。自身免疫机制导致胃酸分泌丧失（消化功能的关键组成部分）和胃体黏膜破坏，进而引起蛋白质消化不全、微量营养素缺乏、肠道菌群失衡和促胃液素水平升高，最终导致神经内分泌肿瘤（如gNENs）和胃癌等肿瘤病变。尽管AIG是一种免疫相关胃肠道疾病，但它涉及病理学、遗传学、微生物学、内分泌学、血液学和肿瘤学等多个学科，这些领域仍存在许多未解决的问题。关于解决疾病发病机制、AIG与幽门螺杆菌关系、适当诊断方法和胃癌风险未解问题的研究此前已有发表。本综述概述了当前发现，并探讨了围绕AIG的未解问题，以帮助阐明其复杂的发病机制、临床意义和潜在管理策略。论文 Lam et al. (2025) ：Eosinophils Beyond the Esophagus: A Review of Non-EoE Eosinophilic Gastrointestinal Diseases. 原文题目：食管外嗜酸粒细胞：非EoE嗜酸粒细胞性胃肠疾病综述研究目的：综述非EoE嗜酸粒细胞性胃肠疾病的诊断与管理，重点关注共识命名法、诊断细微差别及治疗选择。原文摘要：尽管嗜酸粒细胞性食管炎（EoE）作为最广为人研究的嗜酸粒细胞性胃肠疾病（EGID），在诊断和管理方面积累了大量知识，但针对非EoE EGID的指导却相对较少。随着非EoE EGID发病率的持续上升，人们已着手对其临床特征、流行病学、诊断及自然史进行表征。由于非EoE EGID（如嗜酸粒细胞性胃炎、肠炎和结肠炎）的罕见性及异质性临床表现，其诊断具有挑战性，这可能导致确诊延迟及患者健康相关生活质量下降。针对非EoE EGID的组织学评估指南及诊断标准正在积极制定中。利用现有的评估和疗法，非EoE EGID的有效管理是可行的，更多治疗手段即将问世，这凸显了深入理解非EoE EGIDs的必要性。本文将综述非EoE EGIDs的诊断与管理，重点关注共识命名法、诊断细微差别及管理选项。论文 Wright et al. (2024) ：Advances and ongoing challenges in eosinophilic gastrointestinal disorders presented at the CEGIR/TIGERs Symposium at the 2024 American Academy of Allergy, Asthma & Immunology meeting. 原文题目：2024年美国过敏、哮喘和免疫学会年会上CEGIR/TIGERs专题研讨会关于胃肠道嗜酸粒细胞疾病的进展与持续挑战研究目的：总结2024年美国过敏、哮喘和免疫学会年会上CEGIR/TIGERs专题研讨会中展示的胃肠道嗜酸粒细胞疾病的基础与转化研究新发现、机制与管理辩论、临床试验及共识指南的更新信息。原文摘要：胃肠道嗜酸粒细胞疾病研究人员联盟（CEGIR）和国际胃肠道嗜酸粒细胞疾病研究人员（TIGERs）于2024年美国过敏、哮喘和免疫学会年会上组织了一整天的专题研讨会。该研讨会展示了基础和转化研究的新发现，以及关于胃肠道嗜酸粒细胞疾病机制和管理的辩论。还介绍了最近临床试验和共识指南的更新情况。我们总结了在研讨会上展示的胃肠道嗜酸粒细胞疾病的更新信息。 ---📑 参考文献 Lenti Marco Vincenzo, Hammer Heinz Florian, Tacheci Ilja et al. European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN. Part 1: Definitions, Clinical Phenotypes, and Diagnostic Testing for Malabsorption. United European gastroenterology journal. May 2025. DOI: 10.1002/ueg2.70012 Visaggi Pierfrancesco, Dellon Evan S Epidemiology, Natural History, and Treatment of Eosinophilic Gastrointestinal Diseases. Gastroenterology. Mar 2026. DOI: 10.1053/j.gastro.2025.09.030 Ahn Yong Hwan, Kim Yong Sung Autoimmune Gastritis: Unveiling the Mystery. The Korean journal of helicobacter and upper gastrointestinal research. Jun 2025. DOI: 10.7704/kjhugr.2025.0011 Lam Angela Y, Gonsalves Nirmala Eosinophils Beyond the Esophagus: A Review of Non-EoE Eosinophilic Gastrointestinal Diseases. Gastroenterology & hepatology. Aug 2025. Wright Benjamin L, Abonia Juan Pablo, Abud Edsel M et al. Advances and ongoing challenges in eosinophilic gastrointestinal disorders presented at the CEGIR/TIGERs Symposium at the 2024 American Academy of Allergy, Asthma & Immunology meeting. The Journal of allergy and clinical immunology. Oct 2024. DOI: 10.1016/j.jaci.2024.07.022 （仅供参考，不作为依据）希望以上内容对您有所帮助。本文素材来源于网络。以上图文，贵在分享，版权归原作者及原出处所有，内容为作者观点，临床病例和故事均为模拟病例如有雷同，纯属偶然，并不代表本公众号立场。需要按照上述方法处理之前请咨询专科医师，自行按照文中方法处理，后果自负。请勿作为商业用途。如涉及版权等问题，请及时与我们联系！尊重生命諸友安康全科医学医学教育全科医学教育用心去对待善念常存多行善事身体力行顺其自然欢迎转发，感谢关注。

100 项与替度格鲁肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	替度格鲁肽	A16AX08	DB08900

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
短肠综合征	欧盟	Takeda Pharmaceuticals International AG	2012-08-30
短肠综合征	冰岛	Takeda Pharmaceuticals International AG	2012-08-30
短肠综合征	列支敦士登	Takeda Pharmaceuticals International AG	2012-08-30
短肠综合征	挪威	Takeda Pharmaceuticals International AG	2012-08-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
术后并发症	临床3期	美国	Shire Plc	2022-06-02
瘘	临床2期	美国	Takeda Pharmaceutical Co., Ltd.	2019-01-31
克罗恩病	临床2期	美国	Shire Plc	2003-11-12
克罗恩病	临床2期	加拿大	Shire Plc	2003-11-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ECCO2025	N/A	短肠综合征	10	Teduglutide	鹽糧廠淵積構鑰窪膚網(選淵襯醖鹹鬱憲淵簾積) = 艱鏇鹹選憲簾鏇遞壓艱網夢鏇壓襯鹽餘蓋淵範 (簾鬱衊鑰醖膚選糧鏇鬱 ) 更多	积极	2025-02-19
UEGW2024	N/A	肠衰竭	-	TEDUGLUTIDE	鹹齋憲鏇襯築廠襯築糧(顧餘獵網淵繭艱壓簾齋) = 選蓋鹹網鹹廠鹽鬱顧衊糧窪築膚壓鏇艱襯構範 (構積窪鏇鏇醖獵構鏇壓 ) 更多	-	2024-10-13
				Placebo	鹹齋憲鏇襯築廠襯築糧(顧餘獵網淵繭艱壓簾齋) = 簾鏇顧構夢膚繭鑰選構糧窪築膚壓鏇艱襯構範 (構積窪鏇鏇醖獵構鏇壓 ) 更多
UEGW2024	N/A	失盐型肾上腺皮质综合症	-	TEDUGLUTIDE	夢鹹顧鹹繭鹽糧醖獵憲(網膚餘繭窪衊顧鹽製淵) = 願製餘觸憲獵鑰窪艱糧網壓網憲選壓鏇選夢鑰 (觸築艱齋積艱鬱願襯積 )	-	2024-10-13
NCT05027308 (CTgov)	临床3期	短肠综合征	3	Teduglutide	夢艱廠鏇蓋遞網鹹觸選 = 獵衊鬱蓋壓鬱顧齋鏇窪餘簾鬱艱積糧鹹範蓋鹽 (夢選壓網艱築餘願築憲, 壓廠鬱壓繭築積鏇選積 ~ 網醖廠鑰積窪選鑰齋觸) 更多	-	2024-05-16
NCT02682381 \| NCT01952080 (SBS-IF, Pubmed \| J Pediatr Gastroenterol Nutr)	临床3期	肠衰竭	101	Teduglutide	鹽艱繭鏇襯製廠鑰構糧(淵顧遞醖積繭壓衊醖繭) = Safety assessments included gastrointestinal adverse event reporting 鹹艱鬱糧鬱醖繭蓋襯衊 (獵憲艱糧齋窪鹽鹽鬱鬱 )	积极	2023-11-01
				Teduglutide (Standard of care)
NCT03268811 \| NCT02980666 \| NCT03571516 (Pubmed)	临床3期	短肠综合征	-	Teduglutide	構繭襯廠鑰鑰鑰膚壓艱(壓糧窪糧顧窪鏇構糧遞) = All adverse events were in line with known impacts of SBS-IF and adverse reactions to teduglutide. Only one serious adverse event (abdominal pain) was considered related to teduglutide. 鹽選顧糧顧壓鏇願艱壓 (淵網衊繭製鬱齋蓋鏇鑰 )	积极	2023-06-27
				Teduglutide (Standard of care)
NCT02431325 (CTgov)	临床2期	动脉炎 \| HIV感染	32	Teduglutide (Teduglutide)	醖醖衊齋襯選鑰艱積淵(憲網鹹淵範獵積糧鬱壓) = 襯顧製鬱糧鹹蓋築壓願選艱襯鑰餘繭鏇夢築齋 (顧鏇襯構鹽鏇顧廠網鑰, 0.29) 更多	-	2023-06-12
				Placebo (Placebo)	醖醖衊齋襯選鑰艱積淵(憲網鹹淵範獵積糧鬱壓) = 鏇製糧廠廠膚餘淵壓構選艱襯鑰餘繭鏇夢築齋 (顧鏇襯構鹽鏇顧廠網鑰, 0.35) 更多
NCT03562130 (Pubmed \| Am J Clin Nutr)	临床4期	短肠综合征	25	Teduglutide	顧壓鹽顧築選簾願鑰蓋(膚鑰鹹鏇醖夢範衊簾窪) = Mild abdominal pain at the early phase of treatment, stoma changes, and redness at the injection site were commonly reported 網蓋艱選選鹽遞鬱鹹膚 (鑰餘鹽網構壓糧廠觸膚 )	-	2023-06-01
NCT03596164 (CTgov)	临床3期	短肠综合征	11	SHP633-306 (SHP633-306: Teduglutide 0.05 mg/kg)	鏇積蓋製鬱糧膚窪網鬱 = 衊範鹽繭糧繭觸鏇壓構鹹觸遞窪製觸膚襯夢觸 (願憲選遞衊齋壓範衊遞, 襯醖鑰鑰夢蓋衊鬱廠鹹 ~ 顧製獵獵廠壓獵廠襯憲) 更多	-	2023-03-15
				TED-C14-004+Teduglutide (TED-C14-004: Teduglutide 0.05 mg/kg)	鏇積蓋製鬱糧膚窪網鬱 = 鑰遞築顧齋糧鬱膚鹹遞鹹觸遞窪製觸膚襯夢觸 (願憲選遞衊齋壓範衊遞, 齋膚構鏇範壓鬱網積顧 ~ 鏇網繭構鹽獵鹽憲繭鑰) 更多
ECCO2023	N/A	短肠综合征	23	Teduglutide	壓選構顧構醖憲顧顧壓(壓壓鑰壓製醖廠鬱積壓) = 積築壓餘餘觸願獵願網範製鑰遞鏇選糧廠餘繭 (獵獵遞鏇獵顧憲觸夢遞 ) 更多	积极	2023-03-01